Key result
Administration of promethazine and intramuscular ziprasidone in a post-liver transplant patient triggered atypical neuroleptic malignant syndrome without elevated creatine kinase.
Case Report (n=1)
Highlights the importance of rapid diagnosis and management of atypical NMS presenting without elevated creatine kinase.
Answers are grounded in this paper and cite their sources.
Atypical NMS without CK elevation warrants vigilance in post-transplant patients on these agents; single case leaves open generalizability.
Neuroleptic malignant syndrome (NMS) in the absence of an elevated creatine kinase is atypical and more difficult to diagnose. We present a patient with NMS significant risk factors who developed atypical NMS 6 days after a liver transplant. Symptoms of hyperthermia, altered mental status, dyskinesia, and autonomic instability (hypertension and tachycardia) coincided with promethazine administration, with rapid progression to fulminant NMS with lead pipe rigidity after a single injection of intramuscular ziprasidone. Rapid diagnosis and management resulted in full patient recovery. Differential diagnoses for NMS are discussed and a treatment algorithm is proposed.
No takes yet. Share an insight, caveat, or question.
Schreiner et al. (2017) conducted a case report in Atypical Neuroleptic Malignant Syndrome (n=1). Promethazine and ziprasidone was evaluated on Development of atypical NMS and recovery. Administration of promethazine and intramuscular ziprasidone in a post-liver transplant patient triggered atypical neuroleptic malignant syndrome without elevated creatine kinase.
Synapse has enriched 10 related papers. Consider them for comparative context: